Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 63 Published: November 30, 2021 Report Code: GMDGDHC3011TDB

Tyrosine Protein Kinase CSK, also known as C-terminal Src kinase, is an enzyme that, in humans, is encoded by the CSK gene. It plays an important role in the regulation of cell growth, differentiation, migration, and immune response. Furthermore, it phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs). To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. It suppresses signaling by various surface receptors including T-cell receptor (TCR) and B-cell receptor (BCR).

The Tyrosine Protein Kinase CSK drugs in development market research report provides comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key therapy areas in the Tyrosine Protein Kinase CSK pipeline products market?

The key therapy areas in the Tyrosine Protein Kinase CSK pipeline products market are oncology, cardiovascular, dermatology, immunology, and respiratory.

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Therapy AreaTyrosine Protein Kinase CSK Pipeline Products Market Analysis by Therapy AreaFor more therapy area insights, download a free report sample

What are the key indications in the Tyrosine Protein Kinase CSK pipeline products market?

The key indications in the Tyrosine Protein Kinase CSK pipeline products market are solid tumor, triple-negative breast cancer (TNBC), actinic (Solar) keratosis, acute myelocytic leukemia (AML, acute myeloblastic leukemia), arrhythmias, asthma, blood cancer, chronic obstructive pulmonary disease (COPD), colon cancer, gastrointestinal tumor, and others.

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Indications

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Indications

For more indication insights, download a free report sample

What are the key mechanisms of action in the Tyrosine Protein Kinase CSK pipeline products market?

The key mechanism of action in the Tyrosine Protein Kinase CSK pipeline products market is Tyrosine Protein Kinase CSK Inhibitor.

What are the key routes of administration in the Tyrosine Protein Kinase CSK pipeline products market?

The key routes of administration in the Tyrosine Protein Kinase CSK pipeline products market are oral, topical, inhalational, and nasal.

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Routes of Administration

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the different molecule types in the Tyrosine Protein Kinase CSK pipeline products market?

The different molecule types in the Tyrosine Protein Kinase CSK pipeline products market are small molecule and synthetic peptide.

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Molecule Type

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Which are the major companies in the Tyrosine Protein Kinase CSK pipeline products market?

The major companies in the Tyrosine Protein Kinase CSK pipeline products market are Athenex Inc, Nuvectis Pharma Inc, and Pulmatrix Inc.

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Companies

Tyrosine Protein Kinase CSK Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Key therapy area Oncology, Cardiovascular, Dermatology, Immunology, and Respiratory
Key indications Solid Tumor, Triple-Negative Breast Cancer (TNBC), Actinic (Solar) Keratosis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Arrhythmias, Asthma, Blood Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Gastrointestinal Tumor, and Others
Key mechanism of action Tyrosine Protein Kinase CSK Inhibitor
Key routes of administration Oral, Topical, Inhalational, and Nasal
Molecule type Small Molecule and Synthetic Peptide
Major companies Athenex Inc, Nuvectis Pharma Inc, and Pulmatrix Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

  • Athenex Inc

    Nuvectis Pharma Inc

    Pulmatrix Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Overview

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Companies Involved in Therapeutics Development

Athenex Inc

Nuvectis Pharma Inc

Pulmatrix Inc

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Drug Profiles

KX-02 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NXP-900 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PUR-1800 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit C Src Kinase for Colon Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CSK for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirbanibulin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UM-164 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Dormant Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Discontinued Products

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) – Product Development Milestones

Featured News & Press Releases

Sep 27, 2021: Almirall launches Klisyri(Tirbanibulin) for the treatment of actinic keratosis in Europe

Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis

May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis

Apr 12, 2021: Pulmatrix to regain full rights to PUR1800 and narrow spectrum kinase inhibitor portfolio

Mar 04, 2021: Pulmatrix provides update on its lung cancer drug candidate PUR-1800

Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis

Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additional territories for tirbanibulin

Feb 11, 2021: Athenex announces New England Journal of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)

Dec 15, 2020: Almirall announces FDA approval of Klisyri (tirbanibulin), a new innovative topical treatment for actinic keratosis

Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis

Mar 02, 2020: Athenex’s partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis

Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment

Sep 11, 2019: Athenex announces initiation of phase I clinical study in china of KX2-36 oral by partner Guangzhou Xiangxue pharmaceutical

Jun 06, 2019: Athenex and PharmaEssentia announce positive early signals of clinical activity of KX2-391 (INN: tirbanibulin) in patients with Psoriasis

Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Athenex Inc, 2021

Pipeline by Nuvectis Pharma Inc, 2021

Pipeline by Pulmatrix Inc, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.